Luminal potassium ion

Free potassium ions in the gastrointestinal (GI) tract serve as a therapeutic target for the management of hyperkalemia, a condition characterized by elevated systemic potassium levels that can lead to life-threatening cardiac arrhythmias (Palmer & Carrero, 2020, Clinical Journal of the American Society of Nephrology) [2]. In a healthy individual, potassium homeostasis is primarily maintained by the kidneys; however, in patients with chronic kidney disease (CKD) or those taking renin-angiotensin-aldosterone system (RAAS) inhibitors, potassium excretion is often impaired (Palmer & Carrero, 2020) [2]. Pharmacological intervention targets luminal potassium by using non-absorbed binding agents that traverse the GI tract. These agents, such as patiromer and sodium zirconium cyclosilicate, utilize ion-exchange mechanisms to capture free potassium ions in exchange for other cations like calcium, sodium, or hydrogen (FDA Label: Veltassa; FDA Label: Lokelma) [3, 4]. By sequestering potassium within the gut lumen, these drugs prevent its absorption into the portal circulation and promote its elimination through feces (Sterns et al., 2010, Journal of the American Society of Nephrology) [5]. This approach effectively reduces the total body potassium burden and lowers serum potassium concentrations to safe levels (FDA Label: Veltassa) [3].

Other names

Luminal potassiumGastrointestinal potassium ionsIntestinal cationsK+ ionsFree potassium ions and other luminal cations in the gastrointestinal tract

Cation exchange within the gastrointestinal lumen to sequester potassium and facilitate its fecal excretion, thereby lowering systemic serum potassium levels [2, 3, 4].